In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.

Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 ...

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

Bladder cancer is a cancer that develops in the bladder. It usually begins in the cells that line the inside of your bladder. Urothelial cells, the cells in the inner lining of your bladder are ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. In many cases, fibroblast growth factor receptor (FGFR) mutations are known to be ...

Results from cohort 2 of the TROPHY-U-01 study showed that sacitizumab govitecan led to rapid responses in patients with ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

"These findings further support nivolumab plus GC as a standard first-line treatment option for cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma," he said.

providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). FLORENCE, Italy & SAN DIEGO & REHOVOT ...